Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanna Castoldi

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Bioscience Reports|September 29, 2016
Angiotensin type-2 (AT-2)-receptor activation reduces renal fibrosis in cyclosporine nephropathy: evidence for blood pressure independent effectGiovanna Castoldi, Cira R T di Gioia, Raffaella Carletti, et al.
Journal of Hypertension|June 13, 2012
Radiofrequency-based carotid wall tracking: a comparison between two different systemsCarlo Palombo, Michaela Kozakova, Nicola Guraschi, et al.
Pharmaceuticals (Basel, Switzerland)|March 28, 2024
Sodium Glucose Cotransporter-2 Inhibitors in Non-Diabetic Kidney Disease: Evidence in Experimental ModelsGiovanna Castoldi, Raffaella Carletti, Francesca Barzaghi, et al.
Acta Diabetologica|September 7, 2018
Activation of angiotensin type 2 (AT2) receptors prevents myocardial hypertrophy in Zucker diabetic fatty ratsGiovanna Castoldi, Cira R T di Gioia, Francesca Roma, et al.
International Journal of Molecular Sciences|December 24, 2021
Angiotensin Type 2 and Mas Receptor Activation Prevents Myocardial Fibrosis and Hypertrophy through the Reduction of Inflammatory Cell Infiltration and Local Sympathetic Activity in Angiotensin II-Dependent HypertensionGiovanna Castoldi, Raffaella Carletti, Silvia Ippolito, et al.
Clinical and Experimental Pharmacology & Physiology|December 25, 2015
Different regulation of miR-29a-3p in glomeruli and tubules in an experimental model of angiotensin II-dependent hypertension: potential role in renal fibrosisGiovanna Castoldi, Cira di Gioia, Fabrizio Giollo, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|March 6, 2015
Brachial and central blood pressure in HIV-infected subjectsAlessandro Maloberti, Dario Dozio, Mauro Betelli, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|March 12, 2020
Resting Whole Body Energy Metabolism in Class 3 Obesity; from Preserved Insulin Sensitivity to Overt Type 2 DiabetesGiuseppina Manzoni, Alice Oltolini, Silvia Perra, et al.
Journal of Cellular Physiology|December 21, 2012
NF-κB mediated miR-26a regulation in cardiac fibrosisChuanyu Wei, Il-Kwon Kim, Sandeep Kumar, et al.
International Journal of Molecular Sciences|July 14, 2023
Cardioprotective Effects of Sodium Glucose Cotransporter 2 Inhibition in Angiotensin II-Dependent Hypertension Are Mediated by the Local Reduction of Sympathetic Activity and InflammationGiovanna Castoldi, Raffaella Carletti, Silvia Ippolito, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Bioscience Reports|September 29, 2016
Angiotensin type-2 (AT-2)-receptor activation reduces renal fibrosis in cyclosporine nephropathy: evidence for blood pressure independent effectGiovanna Castoldi, Cira R T di Gioia, Raffaella Carletti, et al.
Journal of Hypertension|June 13, 2012
Radiofrequency-based carotid wall tracking: a comparison between two different systemsCarlo Palombo, Michaela Kozakova, Nicola Guraschi, et al.
Pharmaceuticals (Basel, Switzerland)|March 28, 2024
Sodium Glucose Cotransporter-2 Inhibitors in Non-Diabetic Kidney Disease: Evidence in Experimental ModelsGiovanna Castoldi, Raffaella Carletti, Francesca Barzaghi, et al.
Acta Diabetologica|September 7, 2018
Activation of angiotensin type 2 (AT2) receptors prevents myocardial hypertrophy in Zucker diabetic fatty ratsGiovanna Castoldi, Cira R T di Gioia, Francesca Roma, et al.
International Journal of Molecular Sciences|December 24, 2021
Angiotensin Type 2 and Mas Receptor Activation Prevents Myocardial Fibrosis and Hypertrophy through the Reduction of Inflammatory Cell Infiltration and Local Sympathetic Activity in Angiotensin II-Dependent HypertensionGiovanna Castoldi, Raffaella Carletti, Silvia Ippolito, et al.
Clinical and Experimental Pharmacology & Physiology|December 25, 2015
Different regulation of miR-29a-3p in glomeruli and tubules in an experimental model of angiotensin II-dependent hypertension: potential role in renal fibrosisGiovanna Castoldi, Cira di Gioia, Fabrizio Giollo, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|March 6, 2015
Brachial and central blood pressure in HIV-infected subjectsAlessandro Maloberti, Dario Dozio, Mauro Betelli, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|March 12, 2020
Resting Whole Body Energy Metabolism in Class 3 Obesity; from Preserved Insulin Sensitivity to Overt Type 2 DiabetesGiuseppina Manzoni, Alice Oltolini, Silvia Perra, et al.
Journal of Cellular Physiology|December 21, 2012
NF-κB mediated miR-26a regulation in cardiac fibrosisChuanyu Wei, Il-Kwon Kim, Sandeep Kumar, et al.
International Journal of Molecular Sciences|July 14, 2023
Cardioprotective Effects of Sodium Glucose Cotransporter 2 Inhibition in Angiotensin II-Dependent Hypertension Are Mediated by the Local Reduction of Sympathetic Activity and InflammationGiovanna Castoldi, Raffaella Carletti, Silvia Ippolito, et al.
Pageof 3